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Abstract
Purpose Comparison of efﬁcacy of propiverine extended
release (ER) 30 mg o.d. in the treatment of male OAB
administered as monotherapy (MT) or add-on to a-blockers
(combination treatment, CT) in relation to maximum uri-
nary ﬂow (Qmax) in a non-interventional study.
Methods Men C40 years with OAB symptoms, Qmax
C10 ml/s, prostate volume \40 ml, post-void residuals
(PVR) \100 ml, and IPSS \20 were included. OAB
symptoms, IPSS, and PVR were recorded before and after
12 weeks of treatment. Participants were stratiﬁed by Qmax
(group A C15 ml/s, group B \15 ml/s) and CT vs. MT.
Safety parameters were monitored.
Results A total of 2,219 men participated and were
involved in safety analysis; 1,849 men (mean age 66 years)
fulﬁlled the inclusion criteria and were involved in efﬁcacy
analysis. In group A, 291 men received MT and 479 CT; in
group B, 184 men received MT and 895 CT. OAB symp-
toms improved signiﬁcantly in all groups throughout the
study without differences between MT and CT. IPSS
improvement in group B was less with MT than with CT
(-3.9 vs. -5.2; P\0.001), whereas IPSS improvement
was similar in group A (-4.6 vs. -5.1). Mean PVR change
was not clinically relevant, but two men (0.1%) experi-
enced urinary retention.
Conclusions Under real-life conditions, treatment of
OAB symptoms with propiverine ER is equally effective in
men with MT or CT regardless of baseline Qmax. In men
with reduced Qmax, IPSS improvement is signiﬁcantly
smaller with MT. The incidence of urinary retention during
propiverine ER treatment is low.
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Men with lower urinary tract symptoms due to benign
prostatic hyperplasia (LUTS-BPH) suffer to various
degrees and severity of storage, voiding, and post-mictu-
rition symptoms [1]. Although voiding symptoms are more
frequent, storage symptoms are more bothersome [1–3].
Storage symptoms comprise urgency, frequency, nocturia,
and urgency urinary incontinence and are congruent with
OAB [4]. Traditionally, BPH or related conditions were
blamed for all LUTS in adult men; however, recent anal-
yses demonstrated that [50% of men with LUTS–BPH
have no signs of BOO of which [50% have OAB and
urodynamically conﬁrmed detrusor overactivity [5]. These
men are often treated insufﬁciently with a-blockers alone
[6]. Although treatment of storage symptoms/OAB with
antimuscarinics is effective in both genders, physicians are
still reluctant to prescribe antimuscarinics in adult men due
to the theoretical threat of increasing PVR or urinary
retention.
Several randomized-controlled trials or cohort studies
with antimuscarinics as monotherapy (MT) [7–11]o r
together with a-blockers in combination therapy (CT) [12–
18] in men have demonstrated that OAB symptoms and
IPSS can be effectively reduced with antimuscarinics. The
possible role of CT was mostly tested as add-on of the
antimuscarinic to existing but insufﬁciently effective a-
blocker therapy, which makes it difﬁcult to judge whether
it indicated a beneﬁt of CT or only demonstrated the efﬁ-
cacy of an antimuscarinic in a-blocker non-responders. A
pivotal study has applied the inclusion criteria of both
classical LUTS–BPH and OAB studies and compared the
effects of tamsulosin, tolterodine, and their combination
with those of placebo [9]. With such inclusion criteria,
either MT was only modestly effective when compared to
placebo, whereas CT was effective against a range of
symptoms.
Only one non-interventional study (NIS) has been pub-
lished investigating tolterodine under real-life conditions in
men with OAB and Qmax C15 ml/s, thereby assuming non-
obstructed BPH [19, 20]. However, no real-life data are yet
available for other antimuscarinics or adult men with
decreased baseline Qmax. We, therefore, conducted a NIS
in adult men with normal or reduced Qmax using propi-
verine, a muscarinic receptor antagonist with additional
calcium inﬂux inhibitor [21] and a1-adrenoceptor blocking
properties [22]. The aim of this trial was to evaluate in
adult men with OAB whether (1) efﬁcacy depends on
baseline Qmax, (2) reduction in OAB symptoms with pro-
piverine ER 30 mg alone (MT) is as effective as with CT
using propiverine ER 30 mg together with a-blockers, (3)
reduction in overall symptoms, as measured by IPSS, is as
effective with MT as with CT, and (4) treatment with
propiverine ER 30 mg is safe with regard to PVR and
urinary retention.
Patients and methods
Study design
Between May 2008 and January 2009, 557 ofﬁce-based
urologists in Germany participated in this prospective NIS
that consisted of three visits. At visit 1, the following
parameters were recorded: demographic data, patient his-
tory (including previous or current diseases and medica-
tion), urinanalysis, 24-h bladder diary (urgency episodes,
voiding frequency, nocturia, and incontinence episodes),
IPSS (sum of answers to questions 1–7), Qmax and voided
volume during free uroﬂowmetry, and ultrasonic PVR as
well as prostate volume measurements. At visits 2 and 3,
after four and 12 weeks of treatment with propiverine ER,
the variables of the bladder diary, IPSS, and PVR were
recorded again. Additionally, patient-reported adverse
events were documented. In Germany, approval for NIS by
an ethic committee was not mandatory at this time.
Inclusion and exclusion criteria
Men aged C40 years with OAB symptoms (urgency with
or without urgency incontinence, frequency[8/24 h, noc-
turia C2/night) were treated with propiverine ER 30 mg
o.d. alone (MT) or as add-on to existing treatment with a-
blockers (CT) if they met the following inclusion criteria:
Qmax: C10 ml/s at voided volume C100 ml, PVR\100 ml,
prostate volume\40 ml, and IPSS\20. Exclusion criteria
were the following: current or recurrent urinary tract
infection, stress incontinence, catheterization, neurological
history or neurogenic bladder dysfunction, history of lower
urinary tract surgery within the last 6 months, use of 5a-
reductase inhibitors, bladder or prostate cancer, or inter-
stitial cystitis/painful bladder syndrome.
Efﬁcacy and safety analyses
OAB symptoms and IPSS were analyzed using the intent-
to-treat (ITT) population, deﬁned as patients who met
inclusion and exclusion criteria, received at least one dose
of propiverine ER 30 mg, and had at least two visits. The
ITT population was post hoc stratiﬁed by Qmax (C15 ml/s
vs.\15 ml/s) and the use of MT vs. CT. All adverse events
were monitored throughout the observational period
(baseline to week 4 or 12). Patients who took at least one
dose of propiverine were included in the safety analysis.
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123Statistical analysis
For descriptive statistics, we report means with 95% con-
ﬁdence intervals. Signiﬁcance of baseline-end data were
calculated with the two-sided paired t-tests and intergroup
analysis by independent samples t-test. A signiﬁcance level
of 5% was applied for all statistical tests. Statistical ana-
lysis was performed with SAS
 software (Cary, NC, USA).
Results
Study population
A total of 2,219 men participated in the study and were
involved in safety analysis, of which 1,849 men (83.3%)
were included in the efﬁcacy analysis. Baseline demo-
graphic and clinical data of the ITT population are shown
in Table 1. Arterial hypertension (21.7%) and diabetes
mellitus (12.2%) were the most common concomitant
diseases and responsible for the majority of co-medications
used prior to the study.
At study entry, 770 men (41.6%) had Qmax C15 ml/s
(group A) and 1,079 men (58.4%) had Qmax \15 ml/s
(group B). In group A, 291 (37.8%) and 479 men (62.2%)
received MT and CT, respectively. In group B, 184 men
(17.1%) had MT and 895 CT (82.9%). Tamsulosin was the
most commonly used a-blocker (79.9%), followed by
alfuzosin (13.2%). Patients in group B were signiﬁcantly
older, had greater prostate volumes and PVR, more
incontinence episodes, higher voiding frequencies and
nocturia, and lower voided volumes (Table 1). IPSS and
urgency episodes were comparable between the group A
and B.
Efﬁcacy analysis
Diary variables
Signiﬁcant improvements from baseline to study end were
demonstrated for all variables of the bladder diary. For the
overall ITT population, the number of 24-h urgency epi-
sodes declined from 9.4 to 2.8 (mean change -6.4/-68%),
24-h incontinence episodes from 2.0 to 0.3 (mean change
-1.7/-85%), 24-h voiding frequency from 13.5 to 8.1
(mean change -5.4/-40%), and nocturia from 3.5 to 1.5
(mean change -2.1/-60%). The proportion of incontinent
men decreased from 58.2% at beginning of the study to
15.3% at study end. There were no statistical differences
between the outcomes of group A and B as well as between
MT and CT (Table 2).
IPSS
Total IPSS decreased signiﬁcantly from beginning of the
study to week 12 in all four patient groups. While men in
group A exhibited similar efﬁcacy with MT (-4.6) and CT
(-5.1), patients in group B with MT reported a signiﬁ-
cantly smaller IPSS improvement than with CT (-3.7 vs.
-5.3; Fig. 1).
Uroﬂowmetry
No signiﬁcant change in Qmax was observed within group
A (0 ml/s with MT vs. ? 0.2 ml/s with CT; P = 0.768) or
group B (?2.7 ml/s with MT vs. ?3.4 ml with CT;
P = 0.063). However, Qmax was signiﬁcantly different
between the treatment regimes when group A was com-
pared with group B (P\0.001).
Table 1 Baseline and clinical data of all patients of the ITT population and comparison between group A (Qmax C15 ml/s) and group B
(Qmax\15 ml/s); values given as means and 95% conﬁdence intervals (95% CI)
Parameter All participants
(n = 1,849)
Group A
(n = 770)
Group B
(n = 1,079)
P-value
(Group A vs. B)
Mean age (years) 66.0 (65.6–66.5) 64.3 (63.6–65.0) 67.3 (66.7–67.8) <0.001
IPSS 16.9 (16.4–17.2) 16.6 (16.2–16.9) 17.2 (16.7–17.6) 0.706
Prostate volume (ml) 37.2 (36.6–37.7) 34.9 (34.1–35.8) 38.7 (38.0–39.4) <0.001
Qmax (ml/s)
 14.8 (14.5–15.1) 19.4 (18.8–20.0) 11.5 (11.4–11.6) Not applicable
Voided volume (ml)
 209 (206–212) 223 (218–229) 199 (195–203) <0.001
Post-void residual urine (ml) 36 (34–37) 28 (26–30) 41 (39–43) <0.001
Urgency episodes/24 h (n) 9.4 (9.1–9.6) 9.7 (9.3–10.2) 9.1 (8.8–9.4) 0.099
Incontinence episodes/24 h (n) 2.0 (1.9–2.2) 1.9 (1.7–2.1) 2.1 (2.0–2.3) 0.001
Voiding frequency/24 h (n) 13.5 (13.3–13.7) 13.4 (13.1–13.6) 13.6 (13.3–13.8) 0.025
Nocturia (n) 3.5 (3.5–3.6) 3.4 (3.3–3.5) 3.7 (3.5–3.8) 0.005
Qmax Maximum urinary ﬂow rate, IPSS International Prostate Symptom Score
 Obtained by free uroﬂowmetry
Signiﬁcant values are indicated in bold
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123In group A, mean voided volumes increased by 40 and
46 ml with MT and CT, respectively (P = 0.301). In group
B, mean voided volume increased by 35 and 52 ml with
MT and CT, respectively, but the increase was signiﬁcantly
higher for CT (P\0.001).
Safety and tolerability analysis
Post-void residual volume or urinary retention
Mean PVR change was not clinically relevant during the
treatment period. At week 12, mean PVR decreased to
22 ml in group A (-6 ml) and 27 ml in group B (-15 ml).
Despite the overall reduction in mean PVR, 412 patients
(18.6%) of the safety population had PVR increase (mean
?19 ml, range 5–250 ml) including 154 men (6.9%) with
PVR increase of C20 ml (mean increase ?35 ml, mean
PVR: 57 ml) but only two men experienced acute urinary
retention requiring catheterization (one with CT and
baseline Qmax 15.0 ml/s; the other with MT and baseline
Qmax 9.0 ml/s).
Treatment discontinuation and adverse events
Two thousand and seventy patients (93.3%) completed the
study. Sixty men (2.7%) were lost to follow-up and 89 (4%)
discontinued the study. The reasons for premature treatment
terminationwereinsufﬁcientefﬁcacy(1.1%),adverseevents
(0.9%), or patient desire (0.8%). Ten men (0.5%) with
increased PVR (mean baseline PVR 50 ml and increase to
125 ml during the ﬁrst 4 weeks) and two men (0.1%) with
urinary retention also discontinued the treatment.
Adverse drug reactions were reported by 108 patients
(4.9%) of which xerostomia (3.6%), constipation (0.9%),
dizziness (0.3%), and accommodation disorder (0.3%)
occurred most frequently.
Discussion
Although it often remains unclear in clinical practice
whether male LUTS are caused by BPH and/or OAB,
convincing evidence has accumulated that men can beneﬁt
from antimuscarinics, particularly when storage symptoms
dominate and/or insufﬁcient treatment response has been
obtained by prior a-blocker treatment. Key questions for
clinical practice are who beneﬁts from an antimuscarinic,
who from a-blocker, and who from CT? The presence of
BOO may be one criterion to make this choice, particularly
because it remains unclear whether the fear of urinary
retention by exposing men with enlarged prostates to an-
timuscarinics is warranted. Therefore, we have explored in
a real-life setting whether efﬁcacy of propiverine differs
between men with C15 ml/s and\15 ml/s and how this is
affected by MT and CT.
Critique of methods
NIS and randomized-controlled trials have distinct advan-
tages and disadvantages. While controlled trials have high
internal validity due to randomization, blinding, and, in
most cases, source data monitoring, they have limited
external validity because they typically recruit somewhat
artiﬁcial populations due to their strict inclusion and
exclusion criteria. In contrast, NIS have limited internal
validity due to their lack of a control group but have a
greater external validity because they have less rigorous
inclusion and exclusion criteria and, hence, are more rep-
resentative for patients receiving treatment in real practice.
Therefore, NIS cannot substitute for controlled trials but
rather provide complementary evidence. A NIS cannot
provide information on the absolute efﬁcacy or safety of a
drug and such data have already been reported for propi-
verine from randomized-controlled trials [23].
Qmax assessment does not substitute for a vigorous BOO
evaluation by pressure-ﬂow studies but remains the main
approach in routine practice. While Qmax C15 ml/s reﬂects
an absence of BOO in 97% of patients, men with
Qmax \10 ml/s have bladder dysfunction due to different
causes, e.g. detrusor underactivity or, in 69%, BOO [24].
Qmax 10–14.9 ml/s is more difﬁcult to interpret as it may or
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signiﬁcant difference
between treatment week 4 and 12 (P\0.001)
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123may not indicate BOO. For safety reasons and in line with
the summary of product characteristics of propiverine, we
deﬁned Qmax \10 ml/s as well as limits for PVR and
prostate volume as exclusion criteria in our study. There-
fore, our patient stratiﬁcation primarily compared men with
C15 versus those with 10–14.9 ml/s as a necessary com-
promise between scientiﬁc desirability and practical fea-
sibility in a NIS, generating a comparison of men unlikely
to have BOO versus those at risk of BOO.
Baseline data
Baseline data of the present study are very similar to those
found in NIS with other antimuscarinics performed in
Germany [19, 25–27], indicating that our patients are rep-
resentative for those typically seen by German urologists.
Given that Qmax decreases and prostate size, IPPS, and
incontinence episodes increase with age, it is not surprising
that our two main groups of patients deﬁned by their Qmax
differed somewhat by age, prostate size, or incontinence
episode frequency. However, these differences were sur-
prisingly small. Therefore, we chose to present direct group
comparisons for treatment effects rather than applying
multiple regression models with one or more of those
variables as additional explanatory variables.
Treatment effects
The overall efﬁcacy of propiverine ER in the present NIS
in men was similar to efﬁcacy reported with propiverine
immediate release in a mixed gender population under
controlled conditions. The key ﬁnding of our study is that
propiverine improved storage symptoms similarly in men
with Qmax C15 or 10–14.9 ml/s and MT or add-on to
existing a-blocker treatment. The group with lower Qmax
may comprise men with low-grade BOO and/or with
detrusor underactivity [24]. On mechanistic grounds, low-
grade BOO is unlikely to affect OAB improvement by
antimuscarinics. Detrusor underactivity could impair efﬁ-
cacy of an antimuscarinic in a smooth muscle-centric view
but recent evidence suggests that antimuscarinics act in
part via the urothelium and/or afferent nerves [28]. While
the present data are unsuitable to prove that point, they
certainly are in line with this view.
Perhaps even more interesting is the similar efﬁcacy of
propiverine against OAB symptoms when used as MT or
add-on to a-blocker treatment. In men with LUTS-BPH, a-
blockers are effective against storage symptoms at group
level [3]. The fact that propiverine patients in the CT group
received antimuscarinics as add-on indicates that this group
may represent relative non-responders to a-blockers, a
situation where efﬁcacy of an antimuscarinic is likely.
Noteworthy, the only relevant exception from the similar
efﬁcacy of propiverine in MT and CT is the small, but still
signiﬁcant improvement of IPSS in CT of men with Qmax
\15 ml/s. At present, we have no good explanation for this
ﬁnding but it is in line with studies demonstrating that CT
is superior to both antimuscarinic and a-blocker MT in
reducing IPSS [9].
The overall tolerability in our study was very good, and
adverse drug reactions were reported less frequently than in
randomized-controlled trials with propiverine [23]. This
situation is typical for NIS and has also been observed with
other antimuscarinics [19, 25–27]. A key safety consider-
ation in the use of antimuscarinics in elderly men is the
possible risk of inducing increased PVR/urinary retention.
A meta-analysis showed an incidence of urinary retention
while antimuscarinic treatment in men of 0.8% [29]. In line
with previous controlled studies with propiverine [12, 13,
18], the observed changes in PVR were small and acute
urinary retention occurred only rarely in the present study.
This may at least in part be attributable to study design that
excluded men with the largest risk, i.e. those with BOO and
risk factors, such as existing large PVR or prostates for
safety reasons and in line with the drug label. Moreover, it
is a general impression that retention occurs less frequently
when antimuscarinics are used as add-on to existing a-
blocker treatment, probably because a-blockers per se
reduce the risk of retention in studies up to one year [30].
In this regard, the recently demonstrated a1-adrenoceptor
antagonist properties of propiverine [22] may also have
contributed to the low observed incidence of retention.
Conclusions
Under real-life conditions, the efﬁcacy of propiverine
against storage symptoms is similar in men with Qmax
10–14.9 and C15 ml/s and independent of the use of MT or
add-one use to existing a-blocker treatment. However,
overall IPSS improvement, at least in some groups of men,
may be better with CT than propiverine MT. When certain
safety considerations are followed (Qmax C10 ml/s), pro-
piverine ER with or without concomitant a-blockers causes
only small if any PVR increases and has a very low risk of
urinary retention.
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